| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
183,678,000 |
| Market
Cap: |
5.22(B) |
| Last
Volume: |
775,760 |
Avg
Vol: |
769,986 |
| 52
Week Range: |
$26.13 - $36 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Delivery |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 793 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Alkermes is a biopharmaceutical company. Co. has a portfolio of marketed products focused on central nervous system disorders such as addiction and schizophrenia and a pipeline of product candidates in the fields of neuroscience and oncology. Co.'s proprietary products include: ARISTADA, which is an extended-release intramuscular injectable suspension approved in the U.S. for the treatment of schizophrenia; ARISTADA INITIO, which is indicated for the initiation of ARISTADA when used for the treatment of schizophrenia in adults; and VIVITROL, which is for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence, following opioid detoxification.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
22,000 |
22,000 |
485,933 |
663,686 |
| Total Sell Value |
$674,418 |
$674,418 |
$16,213,150 |
$21,682,125 |
| Total People Sold |
1 |
1 |
3 |
4 |
| Total Sell Transactions |
3 |
3 |
11 |
21 |
| End Date |
2025-09-11 |
2025-06-10 |
2024-12-10 |
2023-12-11 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hopkinson Craig C. |
EVP R&D, Chief Medical Officer |
• • – |
2025-12-01 |
4 |
AS |
$29.30 |
$117,200 |
D/D |
(4,000) |
65,740 |
|
2% |
|
| Hopkinson Craig C. |
EVP R&D, Chief Medical Officer |
• • – |
2025-11-03 |
4 |
AS |
$30.38 |
$273,442 |
D/D |
(9,000) |
69,740 |
|
-2% |
|
| Hopkinson Craig C. |
EVP R&D, Chief Medical Officer |
• • – |
2025-11-03 |
4 |
OE |
$19.34 |
$96,700 |
D/D |
5,000 |
78,740 |
|
- |
|
| Hopkinson Craig C. |
EVP R&D, Chief Medical Officer |
• • – |
2025-10-15 |
4 |
AS |
$31.53 |
$283,776 |
D/D |
(9,000) |
73,740 |
|
-8% |
|
| Hopkinson Craig C. |
EVP R&D, Chief Medical Officer |
• • – |
2025-10-15 |
4 |
OE |
$19.34 |
$96,700 |
D/D |
5,000 |
82,740 |
|
- |
|
| Gaffin David Joseph |
EVP, CLO, Alkermes, Inc. |
• • – |
2025-08-03 |
4 |
D |
$26.55 |
$23,762 |
D/D |
(895) |
205,374 |
|
- |
|
| Gaffin David Joseph |
EVP, CLO, Alkermes, Inc. |
• • – |
2025-08-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,014 |
206,269 |
|
- |
|
| Nichols Christian Todd |
SVP, Chief Commercial Officer |
• • – |
2025-06-10 |
4 |
AS |
$31.09 |
$103,654 |
D/D |
(3,334) |
86,208 |
|
-3% |
|
| Nichols Christian Todd |
SVP, Chief Commercial Officer |
• • – |
2025-06-09 |
4 |
AS |
$31.95 |
$106,489 |
D/D |
(3,333) |
89,542 |
|
-1% |
|
| Wright Christopher I |
Director |
• • – |
2025-06-08 |
4 |
D |
$31.71 |
$25,146 |
D/D |
(793) |
23,013 |
|
- |
|
| Wright Christopher I |
Director |
• • – |
2025-06-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,301 |
23,806 |
|
- |
|
| Wright Christopher I |
Director |
• • – |
2025-05-31 |
4 |
D |
$30.61 |
$58,894 |
D/D |
(1,924) |
20,505 |
|
- |
|
| Wright Christopher I |
Director |
• • – |
2025-05-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,013 |
22,429 |
|
- |
|
| Gaynor Richard |
Director |
• • – |
2025-05-31 |
4 |
D |
$30.61 |
$58,894 |
D/D |
(1,924) |
31,084 |
|
- |
|
| Gaynor Richard |
Director |
• • – |
2025-05-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,013 |
33,008 |
|
- |
|
| Mckeon Brian P |
Director |
• • – |
2025-05-31 |
4 |
D |
$30.61 |
$58,894 |
D/D |
(1,924) |
33,869 |
|
- |
|
| Mckeon Brian P |
Director |
• • – |
2025-05-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,013 |
35,793 |
|
- |
|
| Snyderman Nancy Lynn Md |
Director |
• • – |
2025-05-31 |
4 |
D |
$30.61 |
$58,894 |
D/D |
(1,924) |
10,728 |
|
- |
|
| Snyderman Nancy Lynn Md |
Director |
• • – |
2025-05-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,013 |
12,652 |
|
- |
|
| Laurencin Cato T |
Director |
• • – |
2025-05-31 |
4 |
D |
$30.61 |
$58,894 |
D/D |
(1,924) |
29,102 |
|
- |
|
| Laurencin Cato T |
Director |
• • – |
2025-05-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,013 |
31,026 |
|
- |
|
| Lurker Nancy |
Director |
• • – |
2025-05-31 |
4 |
D |
$30.61 |
$58,894 |
D/D |
(1,924) |
10,705 |
|
- |
|
| Lurker Nancy |
Director |
• • – |
2025-05-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,013 |
12,629 |
|
- |
|
| Wilson Frank Anders |
Director |
• • – |
2025-05-31 |
4 |
D |
$30.61 |
$58,894 |
D/D |
(1,924) |
31,084 |
|
- |
|
| Wilson Frank Anders |
Director |
• • – |
2025-05-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,013 |
33,008 |
|
- |
|
1174 Records found
|
|
Page 1 of 47 |
|
|
0.97 (3.3%) 
